Clinical trials: Breast Neoplasms, completed
Breast Cancer
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer.
- Trial name
- NCT00121836
- Testing
- Capecitabine, Bevacizumab
- Where
- 57 sites in United States
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative
The proposed study is a multicenter, open-label phase I trial, conducted in locally advanced or metastatic breast cancer HER2 negative patients and divided into 2 parts: STEP 1: a dose escalation part (n= up to 30) to evaluate…
- Trial name
- GEP14-LEECAP (NCT02754011)
- Testing
- Combination of ribociclib + capecitabine
- Where
- 2 sites in France
- Volunteers
- 18 people
- Sponsor
- UNICANCER
Breast Cancer
Surveillance Imaging Modalities for Breast Cancer Assessment
The purpose of this study is to determine the effectiveness of surveillance breast MRI compared to mammography alone in women with a personal history of breast cancer
- Trial name
- SIMBA (NCT02212834)
- Volunteers
- 36,444 people
- Sponsor
- Kaiser Permanente
Breast Carcinoma
Stakeholder Assessment of Implementing the Commission on Cancer Operative Standards for Cancer Surgery
This study investigates the barriers to implementing breast Synoptic Operative Reports. Information from this study may help researchers identify performance objectives for the breast Synoptic Operative Reports to be adopted…
- Trial name
- NCT05583981
- Testing
- Interview
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors
The main goal of this project is to identify and remediate the cognitive difficulties, including processing speed and attention deficits in individuals who have undergone chemotherapy treatment.
- Trial name
- NCT02515487
- Testing
- Brain Fitness Program (BFP)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- NYU Langone Health
Breast Cancer
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Genomics assays that measure specific gene expression patterns in a patient's primary tumor have become important prognostic tools for breast cancer patients.
- Trial name
- MINT (NCT01501487)
- Testing
- TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy
- Where
- 9 sites in United States
- Volunteers
- 226 people
- Sponsor
- Agendia
Breast Cancer, Ovarian Cancer
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Open-label, cohort study to determine the feasibility and tolerability of the combination of daily niraparib and daily or thrice weekly everolimus for one 28-day cycle in patients with advanced ovarian and breast cancer.
- Trial name
- NCT03154281
- Testing
- niraparib, everolimus
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Breast Cancer
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Trial to optimize neoadjuvant therapy for HER overexpression and co-expressing of hormone receptors(ER and/or PR) breast cancer (HEr2+/HR+).
- Trial name
- ADAPT; T-DM1 (NCT01745965)
- Testing
- T-DM1, Trastuzumab
- Where
- 2 sites in Germany
- Volunteers
- 380 people
- Sponsor
- Women's Cancer Study Group GmbH
Breast Cancer
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard…
- Trial name
- NCT00544167
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 45 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer
Objective Flap Assessment During Reconstructive Surgery
The main purpose of this study is to test the ergonomics of an investigational imaging system that can take pictures of blood vessels under the skin.
- Trial name
- NCT00952107
- Testing
- FLARE imaging system
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
The goal in this Phase 1 dose-escalation trial of the anti-IL-6R monoclonal antibody tocilizumab in combination with trastuzumab and pertuzumab in subjects with metastatic HER2 positive breast cancer is to determine the safety…
- Trial name
- NCT03135171
- Testing
- Trastuzumab, Pertuzumab, Tocilizumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Beast Cancer
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
This phase II trial studies how well exemestane and cyclophosphamide work in treating patients with estrogen receptor (ER) -positive, progesterone receptor (PR) -positive, and human epidermal growth factor receptor…
- Trial name
- NCT01963481
- Testing
- Exemestane, Cyclophosphamide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Breast Cancer
A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
This multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with GDC-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic…
- Trial name
- NCT01740336
- Testing
- GDC-0941, Paclitaxel
- Where
- 97 sites in United States, Australia and 6 more
- Volunteers
- 183 people
- Sponsor
- Genentech, Inc.
Breast Cancer, Perioperative Period
Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality
Breast cancer patients often have sleep disturbances during the perioperative period. Dexmedetomidine is a highly selective alpha 2-adrenoceptor agonist with sedative, anxiolytic, and analgesic effects.
- Conditions
- Breast Cancer, Perioperative Period, Dexmedetomidine, Esketamine
- Trial name
- NCT05732064
- Testing
- Dexmedetomidine, Esketamine, Normal saline
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Peking University First Hospital
Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
This is a first-in-man trial, in which BYL719 will be administered to adult patients with advanced solid tumors, whose tumors have an alteration of the PIK3CA gene and whose disease has progressed despite standard therapy or for…
- Trial name
- NCT01219699
- Testing
- BYL719, Fulvestrant
- Where
- 11 sites in United States, Germany and 3 more
- Volunteers
- 221 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Breast, Diabetes Mellitus
Comorbidities And Reducing inEquitieS
Black cancer patients tend to have worse outcomes than White cancer patients. Some of this disparity may be due to comorbidities.
- Conditions
- Cancer, Breast, Diabetes Mellitus, Hypertension, Cancer Prostate
- Trial name
- CARES (NCT04836221)
- Testing
- Support
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Medstar Health Research Institute
Breast Cancer
Digital Mammography for the Detection and Preoperative Staging of Breast Cancer
Breast tumors are normally seen with mammography or ultrasound without the use of a dye but the size and extent of the tumor may be hard to see.
- Trial name
- NCT01086514
- Testing
- Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Carcinoma, Fallopian Tube Cancer
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
- Trial name
- NCT01091428
- Testing
- Alisertib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 191 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Mammography, Estrogen
Zoladex Plus Tamoxifen in Breast Cancer
The purpose of this study is to compare Zoladex plus tamoxifen with tamoxifen alone as adjuvant hormonal therapy in pre- or perimenopausal women with early-stage breast cancer in terms of breast density, estrogen levels…
- Conditions
- Mammography, Estrogen, Lipemia, Endometrium
- Trial name
- NCT00827307
- Testing
- tamoxifen, Goserelin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Neoplasm
CanRestoreFunction Cancer-related Fatigue ( CRF )
The goal of this randomized control trial is to determine if participating in an 8-week online cancer-related fatigue management intervention consisting of individualized exercise program, one-on-one goal setting and action plan…
- Trial name
- CRF (NCT05868187)
- Testing
- Exercise, Problem-Solving Session and Education
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.